Published Date: 23 Apr 2023
According to the study, prolonged exposure to nitrogen dioxide, particulate matter PM2.5, and nitrogen oxide may raise the risk of dementia.
Read Full NewsBy analyzing data from three clinical trials treating children with the brain tumor medulloblastoma, scientists at St. Jude Children's Research Hospital have designed an approach to safely reduce therapy, thereby lowering ...
Radiotherapy can be safely omitted as a treatment for many breast cancer patients who have had a mastectomy and are taking anti-cancer drugs, a study shows.
People diagnosed with advanced breast cancer in 2025 can expect to live for an extra six or seven months, compared to the average survival time for patients diagnosed in 2011, according to a major study of patient data in ...
1.
Distinct results for patients with positive and negative pancreatic cancer who are treated with systemic therapy, chemotherapy, and radiation.
2.
From sweetener to cancer fighter? Fermented stevia shows promise in pancreatic cancer study
3.
Potentially Novel Approach for Treating Advanced Colorectal Cancer with KRAS Mutations.
4.
GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients.
5.
Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments
1.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
2.
Future of Oncology: Targeted Therapies & Collaborative Innovation Shaping Cancer Care in the USA
3.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
4.
The Ultimate Guide to Understanding Abiraterone and its Uses in Cancer Treatment
5.
Unlocking the Mysteries of Lymphoblastic Lymphoma: A Journey Into the Unknown
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
2.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation